UTMD

In the past six months, Utah Medical Products, Inc. (UTMD) stock has increased by 15.45%, with the share price reaching $69.72 on September 9, 2026, an 11.48% increase from September 11, 2025. The stock's 52-week high was $75.75 on June 25, 2026, and its 52-week low was $53.66 on November 19, 2025. A notable event was the company's announcement on September 22, 2026, of a self-directed Tender Offer to repurchase approximately 20% of its shares at $75 per share, which represented a significant premium and led to a rise in stock price. Financially, the company experienced headwinds in 2Q 2025 and 1H 2025, with consolidated total revenues lower than the previous year, primarily due to decreased sales to a major biopharmaceutical OEM customer, PendoTECH. Gross profit margins also compressed to 56.2% in 2Q 2025 from 60.1% in 2Q 2024, attributed to an unfavorable product mix, lower sales absorbing less fixed manufacturing overhead, higher raw material costs, and an increase in intercompany finished goods inventory. Despite these pressures, UTMD maintains a strong balance sheet with significant cash reserves and negligible debt, consistently paying quarterly dividends, with the last dividend per share being $0.31.